HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2002

Di Leo Angelo, Gancberg David, Larsimont Denis, Tanner Minna, Jarvinen Tero, Rouas Ghizlane, Dolci Stella, Leroy Jean-Yves, Paesmans Marianne, Isola Jorma, Piccart Martine J

Abstract excerpt

PURPOSE: The purpose of this study is to evaluate HER-2 and topoisomerase IIalpha (topo IIalpha) as candidates for predicting the activity of anthracyclines in the adjuvant treatment of breast cancer patients. EXPERIMENTAL DESIGN: In this study, we evaluated HER-2 and topo IIalpha gene aberrations by fluorescence in situ hybridization in a series of 430 primary breast cancer samples. Samples came from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Cyclophosphamide

Share to DNA Topoisomerases, Type II

Share to Fluorouracil

Share to Lymph Nodes

Share to Methotrexate

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed

Identifiers

PMID: 12006526

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.PMID 12006526Read ↗

ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and PredictionSemantic proximity Read ↗

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancerSemantic proximity Read ↗

Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.Semantic proximity Read ↗

Simultaneous Amplification of HER-2 (ERBB2) and Topoisomerase II&#945; (TOP2A) Genes - Molecular Basis for Combination Chemotherapy in CancerSemantic proximity Read ↗

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.Semantic proximity Read ↗

c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective studySemantic proximity Read ↗

Triple negative breast cancer - current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessmentSemantic proximity Read ↗

The role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patientsSemantic proximity Read ↗

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyondSemantic proximity Read ↗

Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes.Semantic proximity Read ↗

HER-2/neu and Topoisomerase IIα Gene Amplification and Protein Expression in Invasive Breast CarcinomasSemantic proximity Read ↗

Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy TrialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.